ALKERMES | ALKS - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -3.27B 628M 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
ALKERMES USD 1.82B 85.86M 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
J&J USD 78.47B 0 2025-09
Malin Corporation EUR 193.2M 75M 2024-12
Merck USD 51.85B 2.79B 2025-09
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Otsuka Holdings JPY 3.03T 174.32B 2025-12
Ovoca Bio EUR 1.26M 7.41M 2025-06
Pfizer USD 92.8B 4.11B 2025-09
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12